Devdatt Kurdikar - 29 May 2025 Form 4 Insider Report for ZIMMER BIOMET HOLDINGS, INC. (ZBH)

Reporting relationship: Director
Issuer ticker: ZBH
Reported as of: 29 May 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 02 Jun 2025, 18:48:41 UTC
Prior SEC filing: 08 Apr 2025
Next SEC filing: 02 Jul 2025
Source filing: View source filing
Reporting owner signature: /s/ Matthew R. St. Louis, Attorney-in-Fact for Devdatt Kurdikar (power of attorney previously filed)

Key filing fact

Devdatt Kurdikar filed Form 4 for ZIMMER BIOMET HOLDINGS, INC. (ZBH) on 02 Jun 2025.

Key facts

This page summarizes Devdatt Kurdikar's Form 4 filing for ZIMMER BIOMET HOLDINGS, INC. (ZBH).
2 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 02 Jun 2025, 18:48.

Change

Previous filing in this sequence was filed on 08 Apr 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001910621 Primary reporting owner

Kurdikar Devdatt

Relationship: Director
Address: 345 E. MAIN STREET, WARSAW
Signature: /s/ Matthew R. St. Louis, Attorney-in-Fact for Devdatt Kurdikar (power of attorney previously filed)
Signature date: 02 Jun 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ZBH transaction Derivative

Phantom Stock Units

Award

Transaction value: $0
Shares: +810
Change %: +159%
Price: $0.000000
Shares after: 1,319
Date: 29 May 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 810
Exercise price: $92.54
Footnotes: F1, F2, F3, F4

ZBH transaction Derivative

Restricted Stock Units

Award

Transaction value: $0
Shares: +1,405
Change %
Price: $0.000000
Shares after: 1,405
Date: 29 May 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 1,405
Exercise price
Footnotes: F2, F5

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 5 footnotes

Footnote F1

The phantom stock units were accrued under the Zimmer Biomet Holdings, Inc. (the "Company") Deferred Compensation Plan for Non-Employee Directors.

Footnote F2

The Conversion or Exercise Price of Derivative Security is 1-for-1.

Footnote F3

These units are to be settled in cash in five annual installments commencing within sixty days after the end of the calendar year in which the cessation of the reporting person's service as a Director occurs.

Footnote F4

Includes 1.192 phantom stock units accrued on April 30, 2025 under the dividend reinvestment provision of the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors.

Footnote F5

The Restricted Stock Units are immediately 100% vested and will be subject to mandatory deferral until the later of (1) the reporting person's termination of service as a Director or (2) the date that is three years after the grant date.